A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke

Brain Research

Volumn 892, Issue 2, 2001, Pages 344-350

  Dawson, Deborah A ^a,b   Wadsworth, Graham ^a,c   Palmer, Alan M ^a  

^a Vernalis (RandD) Ltd   (United Kingdom)

^b VERTEX PHARMACEUTICALS   (United States)

^c Merck Sharp & Dohme Limited   (United Kingdom)

Author keywords

Cerebral ischemia; Excitotoxicity; Middle cerebral artery occlusion; Motor coordination; Neuroprotection; Therapy

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; APTIGANEL; CLOMETHIAZOLE; DIZOCILPINE; GAVESTINEL; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N TERT BUTYL ALPHA (2 SULFOPHENYL) NITRONE; NEUROPROTECTIVE AGENT; REMACEMIDE; RILUZOLE; SIPATRIGINE; SPBN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR COORDINATION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ASPARTIC ACID; CEREBROVASCULAR ACCIDENT; EXTRACELLULAR SPACE; GLUTAMIC ACID; HYPOXIA-ISCHEMIA, BRAIN; MALE; MICE; MICE, INBRED C57BL; MIDDLE CEREBRAL ARTERY; MUSCULOSKELETAL EQUILIBRIUM; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0035936964     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)03269-8     Document Type: Article

References (46)

1. Temporary middle cerebral artery occlusion in the rat: Consistent protocol for a model of stroke and reperfusion
2. A mouse model of focal cerebral ischemia for screening neuroprotective drug effects
3. Lacunar infarcts. Pathogenesis and validity of the clinical syndromes
4. The glycine antagonist Gavestinel protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat
5. Massive persistent release of excitatory amino acids following human occlusive stroke
6. Ifenprodil and eliprodil: Neuroprotective NMDA receptor antagonists and calcium channel blockers
7. Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbances of motor coordination
8. Clinical trials with neuroprotective drugs in acute ischemic stroke: Are we doing the right thing?
9. Clinical trial update: Neuroprotection against ischaemic stroke
10. Drug development for stroke: Importance of protecting cerebral white matter
11. Pathobiology of ischaemic stroke: An integrated view
12. Remacemide hydrochloride: A double blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke
13. Safety and tolerability of Gavestinel (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke
14. Neuroprotection of acute ischemic stroke: Where are we?
15. Mechanisms of ischemic damage to central white matter axons: A quantitative histological analysis using rat optic nerve
16. 125I]albumin
17. The pharmacotherapy of focal cortical ischemia in the mouse
18. Clomethiazole (Zendra) in acute ischemic stroke: Basic pharmacology and biochemistry and clinical efficacy
19. The current status of neuronal protective therapy: Why have all neuronal protective drugs worked in animals but none so far in stroke patients?
20. Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor
21. Nitrone-based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies
22. Neuroprotective therapy
23. Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: Relationship with phencyclidine-like behavioral effects
24. Ligands of the NMDA receptor-associated glycine recognition site and motor behavior
25. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat
26. Cerestat and other NMDA antagonists in ischemic stroke
27. Does neuroprotection improve stroke outcome?
28. NXY-059: Tolerability and pharmacokinetic results in patients with acute stroke
29. Glycine antagonist (gavistinel) in neuroprotection (GAIN international) in patients with acute stroke: A randomized controlled trial
30. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter
31. Focal ischemia enhances the adverse effect potential of N-methyl-D-aspartate receptor antagonists in rats
32. Riluzole in amyotrophic lateral sclerosis
33. Development of the NMDA ion-channel blocker, aptiganel hydrochloride, as a neuroprotective agent for acute CNS injury
34. Gavestinel
35. Neuroprotection for acute stroke. Making clinical trials work
36. The NBQX story
37. Excitatory amino acids and neurodegeneration
38. Preclinical and clinical aspects of remacemide hydrochloride
39. The low-affinity, use-dependent NMDA receptor antagonist AR-R 15896AR. An update of progress in stroke
40. Continuing ischemic damage after acute middle cerebral artery infarction in humans demonstrated by short-echo proton spectroscopy
41. Selfotel (CGS19755)
42. Improved therapeutic window for treatment of histotoxic hypoxia with a free radical spin trap
43. Clomethiazole acute stroke study (CLASS). Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients
44. N-methyl-D-aspartate antagonists for stroke and head trauma
45. Ebselen in acute ischemic stroke
46. Factors determining the therapeutic window for stroke